- Home
- PHAR vs KOS Comparison
PHAR vs KOS Comparison
Compare PHAR & KOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- KOS
- Stock Information
- Founded
- PHAR 1988
- KOS 2003
- Country
- PHAR Netherlands
- KOS United States
- Employees
- PHAR N/A
- KOS N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- KOS Oil & Gas Production
- Sector
- PHAR Health Care
- KOS Energy
- Exchange
- PHAR Nasdaq
- KOS Nasdaq
- Market Cap
- PHAR 718.1M
- KOS 817.4M
- IPO Year
- PHAR N/A
- KOS 2011
- Fundamental
- Price
- PHAR $11.24
- KOS $1.80
- Analyst Decision
- PHAR Strong Buy
- KOS Strong Buy
- Analyst Count
- PHAR 3
- KOS 6
- Target Price
- PHAR $30.00
- KOS $4.93
- AVG Volume (30 Days)
- PHAR 3.1K
- KOS 11.3M
- Earning Date
- PHAR 05-08-2025
- KOS 05-06-2025
- Dividend Yield
- PHAR N/A
- KOS N/A
- EPS Growth
- PHAR N/A
- KOS N/A
- EPS
- PHAR N/A
- KOS N/A
- Revenue
- PHAR $320,708,000.00
- KOS $1,546,854,000.00
- Revenue This Year
- PHAR $13.31
- KOS N/A
- Revenue Next Year
- PHAR $7.68
- KOS $11.51
- P/E Ratio
- PHAR N/A
- KOS N/A
- Revenue Growth
- PHAR 24.13
- KOS N/A
- 52 Week Low
- PHAR $6.65
- KOS $1.39
- 52 Week High
- PHAR $11.07
- KOS $6.22
- Technical
- Relative Strength Index (RSI)
- PHAR 69.87
- KOS 49.00
- Support Level
- PHAR $10.02
- KOS $1.65
- Resistance Level
- PHAR $10.89
- KOS $1.76
- Average True Range (ATR)
- PHAR 0.23
- KOS 0.10
- MACD
- PHAR 0.11
- KOS 0.01
- Stochastic Oscillator
- PHAR 100.00
- KOS 33.05
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.